Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Leiomyosarcoma 1

Interventions

Sorafenib 42lenvatinib 21Fluorouracil 16atezolizumab 15Oxaliplatin 14Bevacizumab 13Doxorubicin 12Radiosurgery 11Leucovorin 11Radiofrequency Ablation 10Ethiodized Oil 10pembrolizumab 7Folfox protocol 7sintilimab 6durvalumab 6Radiotherapy 6Nivolumab 6Epirubicin 6Cisplatin 6tremelimumab 5Gemcitabine 5apatinib 4Embolization, Therapeutic 4tislelizumab 3camrelizumab 3cabozantinib 3Tenofovir 3Pharmaceutical Preparations 3Mitomycin 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Hepatocellular × ADI PEG20 × Clear all
NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Polaris Group

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01287585 2019-09-06

ADI-PEG 20

Polaris Group

Phase 3 Completed
636 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡